PRRT2 and biliary tract cancer: The data suggested that iCCA is a biologically unique disease with distinct molecular targets compared with other biliary tract cancers.8 These findings can have important implications as biomarker-driven clinical trials have shown a clear survival benefit for patients with advanced biliary tract cancers who received matched molecular targeted agents.9